Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Express ...

Background: Postoperative atrial fibrillation (AF) after cardiac surgery is common and is associated with substantial clinical and economic repercussions. However, existing strategies for preventing ...

Everest Medicines today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited ('CORXEL'). Under the agreement ...

Everest Medicines inks Asset Purchase Agreement with Corxel to develop and commercialize Cardamyst nasal spray in Greater China: Shanghai, China Tuesday, March 24, 2026, 16:00 Hrs ...

Everest Medicines today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited. Under the agreement, the Company has acquired the rights to ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVT Participants using CARDAMYST in clinical studies were 2x more likely to convert ...

MONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of ...